Leerink Partners Cuts BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target to $27.00

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its target price decreased by Leerink Partners to $27.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

A number of other research firms have also recently commented on BBOT. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Stifel Nicolaus lowered their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday. Finally, Oppenheimer began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price on the stock. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.88.

BridgeBio Oncology Therapeutics Stock Down 10.3%

BBOT opened at $4.95 on Thursday. The business has a fifty day moving average of $8.66 and a 200 day moving average of $8.67. The stock has a market cap of $396.84 million, a P/E ratio of -1.79 and a beta of 0.38. BridgeBio Oncology Therapeutics has a 52-week low of $4.90 and a 52-week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. Equities analysts anticipate that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current fiscal year.

Institutional Trading of BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BBOT. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth $63,000. Persistent Asset Partners Ltd bought a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at about $107,000. Squarepoint Ops LLC bought a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at about $144,000. Quadrature Capital Ltd purchased a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $162,000. Finally, BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $313,000. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics News Summary

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: JPMorgan maintained an “overweight” rating while lowering its price target from $25 to $23. Even after the reduction, the target implies substantial potential upside from the recent $4.95 share price. JPMorgan price target update
• Positive Sentiment: Wedbush reiterated its “outperform” rating, signaling that it continues to see meaningful value in BridgeBio Oncology Therapeutics despite the recent selloff. Wedbush reiterates outperform rating
• Neutral Sentiment: The company is narrowing its KRAS strategy. BridgeBio Oncology Therapeutics is focusing its development efforts on a more targeted subset of KRAS-related cancer opportunities. The approach could improve capital allocation and differentiation, but it also increases dependence on a narrower group of clinical programs. BridgeBio Oncology Therapeutics bets on a narrower KRAS strategy
• Negative Sentiment: Analyst downgrades drove renewed selling. Leerink Partners issued a pessimistic forecast, while Wall Street Zen lowered the stock to “strong sell.” These actions have weakened investor sentiment toward the company’s valuation and clinical prospects. Leerink Partners forecast Wall Street Zen strong sell downgrade
• Negative Sentiment: BBOT reached a new 52-week low following the downgrades, reinforcing technical and momentum concerns. The stock’s decline of more than 10% in the recent session occurred alongside unusually heavy trading volume. BridgeBio Oncology Therapeutics new 52-week low Why BBOT stock declined

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.